Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Fresenius Medical Care CEO Ronald Kuerbitz has left the dialysis product and service provider to head up new health care services and technology company agilon health. Fresenius appointed William Valle as his successor, effective January 16.
Since 2014, Valle served as executive vice president responsible for the Dialysis Service Business of Fresenius Medical Care North America (FMCNA), the largest business segment of the company, as well as the Vascular Access business.
Valle joined FMCNA in 2009 with 22 years’ experience in the dialysis industry, holding executive positions at several dialysis companies including Gambro Healthcare, Inc.
Read the full story at Nephrology News.